▶ Freely access a vast video library on NASH and NAFLD, its management and diagnosis along with the latest on pan-PPAR agonist, lanifibranor.
Nash Videos
PPAR’s as Critical Regulators of Metabolism
Prof Roden, Germany explains why PPAR’s are interesting therapeutic targets not only to improve adipose tissue function but also for the liver. The approach can go beyond the improvement of liver function and aim at a more systemic approach with cardiovascular benefits.
View More ⏩PPAR’s as Critical Regulators of Metabolism
PPAR alpha delta : what you need to know about the latest results
Prof Sacks, USA reviews the available data about PPAR alpha delta and the Elafibranor clinical program (RESOVE-IT). The interim results were presented earlier this year. They are somewhat disappointing (especially regarding the primary liver outcome).
View More ⏩PPAR alpha delta : what you need to know about the latest resultsPPAR alpha gamma dual agonists : what you need to know
Prof Sacks, USA reviews the available data about PPAR gamma agonist (Pioglitazone) especially data from the PROACTIVE study published in the Lancet in 2005
View More ⏩PPAR alpha gamma dual agonists : what you need to knowNAFLD and states of insulin resistance
Insulin resistance is tightly linked to NAFLD, particularly in those with Type 2 Diabetes.
In this video, Prof. Michael Roden, Germany discusses this link, its origins that can inherited or acquired. He also sheds light on the consequences of insulin resistance.
View More ⏩NAFLD and states of insulin resistance
The prevalence, risks and costs of NASH
NASH is associated with cardiovascular diseases and cardiovascular mortality. Prof Rosano, UK discusses the prevalence, risks and economic costs of NAFLD and NASH. He sheds lights on the risk of obesity that induces many changes. He also reviews countries with higher prevalence, age characteristics and the incidence and progression of the disease
View More ⏩The prevalence, risks and costs of NASHLipids effects of PPARs by Prof. F. Sacks
Prof Sacks, USA summarises what we know about the PPARs lipid effects. If the strongest evidence is with PPAR-alpha agonists for which the main lipid effect is lowering triglycerids, the are interesting information to discuss about PPAR-delta (Seladelpar).
View More ⏩Lipids effects of PPARs by Prof. F. Sacks
Microvesicles as NAFLD biomarkers: a clinician’s point of view by Prof. P. E. Rautou
Prof Rautou, France, sheds light on microvesicles, which reflect apoptosis and cell activation. He discusses what we know about microvesicles in NASH and the rationale to consider them as biomarkers in liver disease.
View More ⏩Microvesicles as NAFLD biomarkers: a clinician’s point of view by Prof. P. E. RautouThe link between lipids and PPARs in NASH by Prof. F. Sacks
Prof Sacks, Harvard Medical School, discusses the link between PPAR agonists and plasma lipid risk factors for cardiovascular disease. He explains how free fatty acids go to the liver and become lipotoxic. This activates inflammation in the liver which in turn reacts.
View More ⏩The link between lipids and PPARs in NASH by Prof. F. Sacks
Liver biopsy in NASH by Prof. P. Bedossa
In NAFLD, the liver is both victim and motor of a multisystem disease.
Liver disease is not limited to the liver itself but has an impact on glycemic control in the body.
Prof. Tacke discusses this vicious cycle and how NAFLD may add to coexisting risk factors and is predictor of morbidity and mortality. He shows why this is also important to develop new treatment strategies.
View More ⏩Liver biopsy in NASH by Prof. P. Bedossa
The multiple risks in NAFLD by Prof. F. Tacke
In NAFLD, the liver is both victim and motor of a multisystem disease.
Liver disease is not limited to the liver itself but has an impact on glycemic control in the body.
Prof. Tacke discusses this vicious cycle and how NAFLD may add to coexisting risk factors and is predictor of morbidity and mortality. He shows why this is also important to develop new treatment strategies.
View More ⏩The multiple risks in NAFLD by Prof. F. TackeLiver biopsy in NASH clinical trials by Prof. P. Bedossa
Prof. Pierre Bedossa (France) exploring mandatory role liver biopsy plays in clinical trials for NASH and the need for a central pathologist.
View More ⏩Liver biopsy in NASH clinical trials by Prof. P. BedossaRole of PPARs (experimental paper) by Prof. F. Tacke
Prof. Frank Tacke discusses a paper in press in the Journal of Hepatology regarding the role of PPAR’s in experimental models and how these PPAR’s affect the progression of liver disease.
View More ⏩Role of PPARs (experimental paper) by Prof. F. Tacke
SUBSCRIBE & FOLLOW US
SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES